Research programme: heteroaryl oxazolidinones - BayerAlternative Names: Heteroaryl oxazolidinones research programme - Bayer
Latest Information Update: 09 Jul 2002
At a glance
- Originator Bayer
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 02 Feb 1998 New profile
- 02 Feb 1998 Preclinical development for Gram-positive infections in Germany (Unknown route)